FDA accepts UroGen's UGN-103 application for bladder cancer treatment
URGN•The FDA accepted UroGen Pharma’s UGN-103 application to treat adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer and set a June 14, 2027, target action date.
1. Application accepted
The FDA accepted UroGen Pharma’s UGN-103 application to treat adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. The agency set a June 14, 2027, target action date.
